Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Endocrinol Metab. 2017 Nov 3. doi: 10.1210/jc.2017-01790. [Epub ahead of print]

Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer with Loforegional Persistent Disease.

Author information

1
Institute of Endocrinology, Rabin Medical Center - Beilinson Hospital, Petach Tikva.
2
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.
3
Endocrine Institute, Assaf Harofeh Medical Center, Zriffin; Israel.

Abstract

Purpose:

Radioactive iodine (RAI) treatment is often indicated after total thyroidectomy in differentiated thyroid cancer (DTC). However, its role in biochemical or loco-regional persistent DTC is unclear. We aimed to investigate the impact of a second RAI treatment in patients with incomplete response to initial treatment and no evidence of distant metastases.

Methods:

Patients who underwent at least two RAI treatments over a 20-year period at a tertiary hospital were identified. Thyroglobulin levels and neck imaging were compared before and 1-2 years after RAI retreatment and evaluated at the last visit.

Results:

The cohort included 164 patients (103 female, mean age 46.6±17 years). Of 114 patients retreated without prior reoperation, 53 had structural disease. At 1-2 years after RIA retreatment, 10 of the 41 patients with sufficient data had structural progression, 5 resolution/shrinkage, and 26 stable disease. Stimulated thyroglobulin (stTg) measured 93.7.1±108 ng/ml before and 102.2±124 ng/ml after retreatment (p=NS). The other 61 patients had biochemical-only persistence. Their stTg level decreased from 41.9±56 to 24.6±54 ng/ml (p=0.003). The 50 patients who underwent neck reoperation before RAI retreatment showed no significant change in stTg; 21 (42%) still had imaging findings 1-2 years later. At final follow-up, despite additional treatment in 63/164 patients (38.4%), only 56/164 (34.1%) had no evidence of disease.

Conclusions:

This comprehensive study showed very limited benefit of second RAI treatment in DTC patients with biochemical or loco-regional structural persistent disease. Prospective studies are needed to distinguish patients for whom repeated RAI may be indicated to avoid unnecessary exposure.

PMID:
29126111
DOI:
10.1210/jc.2017-01790
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center